Background: To analyse available evidence on the efficacy and safety of anti-TNF drugs (infliximab, etanercept and adalimumab) for treating rheumatoid arthritis (RA).

No abstract

The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701).

No abstract

No abstract

No abstract

No abstract

No abstract